Sunstar
Based on this declarative statement alone I believe Bavi is in the drivers seat for multitudes of collaborations once SUNRISE approved.
PD-1 and CTLA-4-targeting drugs have significantly improved patient survival in both melanoma and NSCLC, although their efficacy has been limited to a minority of subjects. Phosphatidylserine (PS)-targeting antibodies have demonstrated the ability to override tumor immune suppression and reactivate immune responses when combined with immunotherapies, chemotherapies, radiation, and targeted treatments. Recent translational data demonstrate the potential of PS-targeting antibodies to mediate immune activation and improved anti-tumor responses in low PD-L1 tumor samples.
News 
Market Data 
Discover 
